News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Views & Analysis Will the UK ever produce a world-class biotech company? Kymab, F-star and Mission Therapeutics among crop of new UK biotechs.
News Mission Therapeutics raises £60m to advance novel ‘DUB’ drug... UK biotech company Mission Therapeutics has raised £60 million to invest into its drug discovery and development programme.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.